Agios Non Current Assets Total vs Common Stock Total Equity Analysis
AGIO Stock | USD 34.79 0.21 0.60% |
Agios Pharm financial indicator trend analysis is way more than just evaluating Agios Pharm prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Agios Pharm is a good investment. Please check the relationship between Agios Pharm Non Current Assets Total and its Common Stock Total Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
Non Current Assets Total vs Common Stock Total Equity
Non Current Assets Total vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Agios Pharm Non Current Assets Total account and Common Stock Total Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Agios Pharm's Non Current Assets Total and Common Stock Total Equity is 0.78. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Agios Pharm, assuming nothing else is changed. The correlation between historical values of Agios Pharm's Non Current Assets Total and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Agios Pharm are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Non Current Assets Total i.e., Agios Pharm's Non Current Assets Total and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.78 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from Agios Pharm's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Agios Pharm current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.At this time, Agios Pharm's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 17th of May 2024, Enterprise Value is likely to grow to about 1.5 B, while Selling General Administrative is likely to drop about 81.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 378.4M | 401.6M | 408.8M | 320.4M | Cost Of Revenue | 18.8M | 1.7M | 9.5M | 9.0M |
Agios Pharm fundamental ratios Correlations
Click cells to compare fundamentals
Agios Pharm Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Agios Pharm fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 890.7M | 853.0M | 1.4B | 1.2B | 937.1M | 752.6M | |
Other Current Liab | 53.1M | 60.1M | 32.0M | 30.4M | 43.2M | 29.6M | |
Total Current Liabilities | 92.9M | 94.4M | 59.8M | 62.6M | 68.0M | 75.2M | |
Total Stockholder Equity | 640.5M | 399.5M | 1.3B | 1.1B | 811.0M | 564.7M | |
Other Liab | 77.4M | 50.6M | 261.3M | 3.3M | 3.8M | 3.6M | |
Property Plant And Equipment Net | 126.1M | 117.5M | 104.2M | 88.1M | 69.8M | 52.5M | |
Net Debt | 32.7M | (22.2M) | (106.0M) | (53.6M) | (16.2M) | (17.0M) | |
Retained Earnings | (1.5B) | (1.8B) | (238.8M) | (470.6M) | (822.6M) | (863.8M) | |
Accounts Payable | 21.9M | 26.8M | 16.7M | 18.6M | 9.8M | 15.9M | |
Cash | 80.9M | 127.4M | 203.1M | 139.3M | 88.2M | 83.8M | |
Non Current Assets Total | 279.0M | 216.3M | 373.5M | 405.9M | 103.3M | 178.4M | |
Non Currrent Assets Other | (279.0M) | 1.1M | 2.9M | 4.0M | 4.1M | 4.3M | |
Cash And Short Term Investments | 564.9M | 670.5M | 1.3B | 1.1B | 776.9M | 637.5M | |
Common Stock Total Equity | 58K | 68K | 69K | 71K | 81.7K | 49.5K | |
Common Stock Shares Outstanding | 60.0M | 69.0M | 60.4M | 54.8M | 55.7M | 48.8M | |
Short Term Investments | 483.9M | 445.5M | 816.9M | 643.9M | 688.7M | 428.3M | |
Liabilities And Stockholders Equity | 890.7M | 853.0M | 1.4B | 1.2B | 937.1M | 752.6M | |
Non Current Liabilities Total | 157.3M | 359.1M | 85.9M | 75.3M | 58.1M | 112.7M | |
Other Current Assets | 24.2M | (74.0M) | 11.8M | 39.0M | 35.0M | 36.8M | |
Other Stockholder Equity | 2.2B | 2.2B | 1.5B | 1.6B | 1.6B | 1.2B | |
Total Liab | 250.2M | 453.5M | 145.8M | 137.9M | 126.1M | 187.9M | |
Property Plant And Equipment Gross | 31.5M | 117.5M | 28.9M | 138.2M | 122.0M | 128.1M | |
Total Current Assets | 611.7M | 636.7M | 1.1B | 832.8M | 833.8M | 574.2M | |
Accumulated Other Comprehensive Income | 202K | 105K | (1.2M) | (12.5M) | (441K) | (463.1K) | |
Short Term Debt | 6.9M | 7.4M | 11.2M | 13.7M | 15.0M | 27.5M | |
Common Stock | 58K | 68K | 69K | 71K | 72K | 51.8K | |
Property Plant Equipment | 31.5M | 32.3M | 28.9M | 23.0M | 26.4M | 21.1M | |
Net Tangible Assets | 640.5M | 399.5M | 1.3B | 1.1B | 1.3B | 633.1M | |
Net Receivables | 15.3M | 25.4M | 4.4M | 2.2M | 2.8M | 2.7M | |
Retained Earnings Total Equity | (1.5B) | (1.8B) | (238.8M) | (470.6M) | (423.5M) | (444.7M) | |
Capital Surpluse | 2.2B | 2.2B | 2.3B | 2.4B | 2.7B | 1.7B | |
Inventory | 7.3M | 14.7M | 16.2M | 8.5M | 19.1M | 20.0M | |
Long Term Investments | 152.9M | 97.6M | 266.4M | 313.9M | 29.4M | 28.0M | |
Non Current Liabilities Other | 157.3M | 359.1M | 85.9M | 3.3M | 1.2M | 1.1M | |
Net Invested Capital | 640.5M | 399.5M | 1.3B | 1.1B | 811.0M | 833.9M | |
Net Working Capital | 518.8M | 542.3M | 1.0B | 770.1M | 765.9M | 702.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Agios Stock analysis
When running Agios Pharm's price analysis, check to measure Agios Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agios Pharm is operating at the current time. Most of Agios Pharm's value examination focuses on studying past and present price action to predict the probability of Agios Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agios Pharm's price. Additionally, you may evaluate how the addition of Agios Pharm to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Agios Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.31) | Revenue Per Share 0.526 | Quarterly Revenue Growth 0.46 | Return On Assets (0.25) | Return On Equity (0.40) |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.